Related Experiment Video
Updated: Nov 8, 2025
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Rationales and uncertainties for aspirin use in COVID-19: a narrative review
Hazem A Sayed Ahmed1, Eric Merrell2, Mansoura Ismail1
1Department of Family Medicine, Suez Canal University Faculty of Medicine, Ismailia, Egypt.
Insights
Low-dose aspirin may reduce intensive care unit admission for hospitalized COVID-19 patients by targeting inflammation and clotting. Further trials are needed to confirm aspirin
Area of Science:
- Cardiovascular Medicine
- Infectious Diseases
- Pharmacology
Background:
- COVID-19 pathogenesis involves endothelial dysfunction, coagulopathy, and inflammation.
- Aspirin exhibits anti-inflammatory, antiplatelet, and anticoagulant properties.
- Existing evidence supports aspirin use in various cardiovascular and inflammatory conditions.
Purpose of the Study:
- To review COVID-19 pathophysiology.
- To identify potential aspirin targets in COVID-19 pathogenesis.
- To evaluate the role of aspirin in COVID-19 patients.
Main Methods:
- A narrative review of literature.
- Searches conducted in PubMed, Ovid Medline, and Cochrane Library (Jan 2016-Jan 2021).
- Inclusion of international guidelines and relevant society recommendations.
Main Results:
- Clinical deterioration in COVID-19 linked to endothelial dysfunction, coagulopathy, and inflammation.
- Aspirin's pleiotropic effects may counteract these mechanisms.
- Prehospital low-dose aspirin may decrease ICU admission and mechanical ventilation needs in COVID-19 patients, though mortality impact is debated.
Conclusions:
- Low-dose aspirin is recommended for primary prevention of arterial thromboembolism in specific at-risk populations.
- Further randomized controlled trials are essential to establish aspirin's causal role in preventing COVID-19-associated acute lung injury, vascular thrombosis, and mortality.
Objectives:
To review the pathophysiology of COVID-19 disease, potential aspirin targets on this pathogenesis and the potential role of aspirin in patients with COVID-19.
Design:
Narrative review.
Setting:
The online databases PubMed, OVID Medline and Cochrane Library were searched using relevant headlines from 1 January 2016 to 1 January 2021. International guidelines from relevant societies, journals and forums were also assessed for relevance.
Participants:
Not applicable.
Results:
A review of the selected literature revealed that clinical deterioration in COVID-19 is attributed to the interplay between endothelial dysfunction, coagulopathy and dysregulated inflammation. Aspirin has anti-inflammatory effects, antiplatelet aggregation, anticoagulant properties as well as pleiotropic effects on endothelial function. During the COVID-19 pandemic, low-dose aspirin is used effectively in secondary prevention of atherosclerotic cardiovascular disease, prevention of venous thromboembolism after total hip or knee replacement, prevention of pre-eclampsia and postdischarge treatment for multisystem inflammatory syndrome in children. Prehospital low-dose aspirin therapy may reduce the risk of intensive care unit admission and mechanical ventilation in hospitalised patients with COVID-19, whereas aspirin association with mortality is still debatable.
Conclusion:
The authors recommend a low-dose aspirin regimen for primary prevention of arterial thromboembolism in patients aged 40-70 years who are at high atherosclerotic cardiovascular disease risk, or an intermediate risk with a risk-enhancer and have a low risk of bleeding. Aspirin's protective roles in COVID-19 associated with acute lung injury, vascular thrombosis without previous cardiovascular disease and mortality need further randomised controlled trials to establish causal conclusions.
More Related Videos
08:36Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
08:56Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...